“Persistent kidney inflammation is a hallmark of IgAN, and a key driver of disease progression, leading to ongoing kidney damage…
First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025UK Clinical Trial Application (CTA) approval shortly…
VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal…